Name | Number of supported studies | Average coverage | |
---|---|---|---|
CD4-positive, alpha-beta T cell | 28 studies | 28% ± 10% | |
T cell | 10 studies | 24% ± 8% | |
CD4-positive, alpha-beta memory T cell | 8 studies | 29% ± 13% | |
naive thymus-derived CD4-positive, alpha-beta T cell | 7 studies | 22% ± 4% | |
T follicular helper cell | 7 studies | 30% ± 7% | |
mucosal invariant T cell | 5 studies | 21% ± 4% | |
effector memory CD4-positive, alpha-beta T cell | 4 studies | 33% ± 12% | |
T-helper 17 cell | 4 studies | 36% ± 6% | |
effector CD4-positive, alpha-beta T cell | 3 studies | 30% ± 7% | |
CD4-positive helper T cell | 3 studies | 26% ± 7% | |
T-helper 1 cell | 3 studies | 45% ± 17% |
Insufficient scRNA-seq data for expression of CD40LG at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 99% | 142.33 | 571 / 578 | 64% | 2.45 | 743 / 1155 |
breast | 73% | 33.31 | 334 / 459 | 63% | 2.77 | 701 / 1118 |
stomach | 65% | 22.09 | 232 / 359 | 68% | 2.36 | 195 / 286 |
intestine | 74% | 112.14 | 711 / 966 | 58% | 1.75 | 306 / 527 |
thymus | 83% | 45.83 | 539 / 653 | 46% | 2.29 | 276 / 605 |
kidney | 53% | 31.89 | 47 / 89 | 69% | 2.35 | 618 / 901 |
prostate | 57% | 23.75 | 139 / 245 | 48% | 1.39 | 240 / 502 |
spleen | 100% | 290.61 | 241 / 241 | 0% | 0 | 0 / 0 |
bladder | 62% | 55.29 | 13 / 21 | 36% | 0.86 | 180 / 504 |
skin | 49% | 18.92 | 892 / 1809 | 40% | 2.15 | 189 / 472 |
adipose | 89% | 54.04 | 1070 / 1204 | 0% | 0 | 0 / 0 |
liver | 46% | 12.65 | 105 / 226 | 41% | 1.20 | 168 / 406 |
peripheral blood | 81% | 322.62 | 756 / 929 | 0% | 0 | 0 / 0 |
uterus | 47% | 13.65 | 80 / 170 | 33% | 0.88 | 153 / 459 |
esophagus | 41% | 16.74 | 587 / 1445 | 38% | 1.15 | 69 / 183 |
lymph node | 0% | 0 | 0 / 0 | 69% | 7.72 | 20 / 29 |
tonsil | 0% | 0 | 0 / 0 | 67% | 2.97 | 30 / 45 |
pancreas | 9% | 1.97 | 31 / 328 | 54% | 2.17 | 96 / 178 |
ovary | 22% | 6.74 | 40 / 180 | 25% | 0.51 | 109 / 430 |
blood vessel | 45% | 20.29 | 601 / 1335 | 0% | 0 | 0 / 0 |
adrenal gland | 16% | 3.78 | 42 / 258 | 6% | 0.09 | 14 / 230 |
heart | 17% | 5.56 | 149 / 861 | 0% | 0 | 0 / 0 |
brain | 2% | 0.52 | 63 / 2642 | 5% | 0.11 | 36 / 705 |
eye | 0% | 0 | 0 / 0 | 6% | 0.13 | 5 / 80 |
muscle | 2% | 0.45 | 15 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0023035 | Biological process | CD40 signaling pathway |
GO_0042102 | Biological process | positive regulation of T cell proliferation |
GO_0006954 | Biological process | inflammatory response |
GO_0032753 | Biological process | positive regulation of interleukin-4 production |
GO_0031295 | Biological process | T cell costimulation |
GO_0032735 | Biological process | positive regulation of interleukin-12 production |
GO_0032733 | Biological process | positive regulation of interleukin-10 production |
GO_0002637 | Biological process | regulation of immunoglobulin production |
GO_0030168 | Biological process | platelet activation |
GO_0051092 | Biological process | positive regulation of NF-kappaB transcription factor activity |
GO_0007229 | Biological process | integrin-mediated signaling pathway |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0042100 | Biological process | B cell proliferation |
GO_0045190 | Biological process | isotype switching |
GO_2000353 | Biological process | positive regulation of endothelial cell apoptotic process |
GO_0030183 | Biological process | B cell differentiation |
GO_0007159 | Biological process | leukocyte cell-cell adhesion |
GO_0005615 | Cellular component | extracellular space |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0009986 | Cellular component | cell surface |
GO_0005178 | Molecular function | integrin binding |
GO_0043539 | Molecular function | protein serine/threonine kinase activator activity |
GO_0005174 | Molecular function | CD40 receptor binding |
GO_0005164 | Molecular function | tumor necrosis factor receptor binding |
GO_0005515 | Molecular function | protein binding |
GO_0005125 | Molecular function | cytokine activity |
Gene name | CD40LG |
Protein name | CD40 ligand CD40 ligand (CD40-L) (Tumor necrosis factor ligand superfamily member 5) CD40 ligand (CD40-L) (T-cell antigen Gp39) (TNF-related activation protein) (TRAP) (Tumor necrosis factor ligand superfamily member 5) (CD antigen CD154) [Cleaved into: CD40 ligand, membrane form; CD40 ligand, soluble form (sCD40L)] CD40 ligand (Tumor necrosis factor ligand superfamily member 5) |
Synonyms | TRAP TNFSF5 CD40L |
Description | FUNCTION: Cytokine that acts as a ligand to CD40/TNFRSF5 . Costimulates T-cell proliferation and cytokine production . Its cross-linking on T-cells generates a costimulatory signal which enhances the production of IL4 and IL10 in conjunction with the TCR/CD3 ligation and CD28 costimulation . Induces the activation of NF-kappa-B . Induces the activation of kinases MAPK8 and PAK2 in T-cells . Induces tyrosine phosphorylation of isoform 3 of CD28 . Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL4 (By similarity). Involved in immunoglobulin class switching (By similarity). .; FUNCTION: [CD40 ligand, soluble form]: Acts as a ligand for integrins, specifically ITGA5:ITGB1 and ITGAV:ITGB3; both integrins and the CD40 receptor are required for activation of CD40-CD40LG signaling, which have cell-type dependent effects, such as B-cell activation, NF-kappa-B signaling and anti-apoptotic signaling. . FUNCTION: Cytokine that acts as a ligand to CD40/TNFRSF5. Costimulates T-cell proliferation and cytokine production. Involved in immunoglobulin class switching. .; FUNCTION: [CD40 ligand, soluble form]: Acts as a ligand for integrins, specifically ITGA5:ITGB1 and ITGAV:ITGB3; both integrins and the CD40 receptor are required for activation of CD40-CD40LG signaling, which have cell-type dependent effects, such as B-cell activation, NF-kappa-B signaling and anti-apoptotic signaling. . FUNCTION: Cytokine that acts as a ligand to CD40/TNFRSF5. Costimulates T-cell proliferation and cytokine production. Involved in immunoglobulin class switching. .; FUNCTION: [CD40 ligand, soluble form]: Acts as a ligand for integrins, specifically ITGA5:ITGB1 and ITGAV:ITGB3; both integrins and the CD40 receptor are required for activation of CD40-CD40LG signaling, which have cell-type dependent effects, such as B-cell activation, NF-kappa-B signaling and anti-apoptotic signaling. . FUNCTION: Acts as a ligand for integrins, specifically ITGA5:ITGB1 and ITGAV:ITGB3; both integrins and the CD40 receptor are required for activation of CD40-CD40LG signaling, which have cell-type dependent effects, such as B-cell activation, NF-kappa-B signaling and anti-apoptotic signaling. . |
Accessions | Q3L8U2 Q45QX2 ENST00000695725.1 ENST00000370629.7 ENST00000370628.2 A0A8Q3WKP2 A0A8Q3WL88 P29965 ENST00000695724.1 C1L3E0 |